Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin‐IntermediateStaphylococcus aureus | Zendy

Patrick G. P. Charles | Zendy; Peter Ward | Zendy; Paul D. R. Johnson | Zendy; Benjamin P. Howden | Zendy; M. Lindsay Grayson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin‐IntermediateStaphylococcus aureus

Author(s) -

Patrick G. P. Charles,

Peter Ward,

Paul D. R. Johnson,

Benjamin P. Howden,

M. Lindsay Grayson

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/381093

Subject(s) - bacteremia , medicine , vancomycin , staphylococcus aureus , staphylococcal infections , micrococcaceae , microbiology and biotechnology , antibiotics , antibacterial agent , bacteria , biology , genetics

We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research